Aurinia Pharmaceuticals Inc. (AUPH)

$9.32

+0.05 (+0.54%)
Rating:
Recommendation:
Neutral
Symbol AUPH
Price $9.32
Beta 0.838
Volume Avg. 3.02M
Market Cap 1.324B
Shares () -
52 Week Range 4.07-20.475
1y Target Est -
DCF Unlevered AUPH DCF ->
DCF Levered AUPH LDCF ->
ROE -26.03% Sell
ROA -23.64% Sell
Operating Margin -
Debt / Equity 15.32% Neutral
P/E -
P/B 3.12 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest AUPH news


Mr. Peter Greenleaf
Healthcare
Biotechnology
NASDAQ Global Market

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.